TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
TG Therapeutics (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in a fireside chat at the B. Riley Securities Neuroscience Conference on April 28, 2021, at 9:00 AM ET. The event will be held virtually, and a live webcast will be available on the company’s website. TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases, with an active research pipeline and FDA-approved UKONIQ™ for specific lymphoma treatments.
- None.
- None.
Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Neuroscience Conference being held virtually. The fireside chat is scheduled to take place on Wednesday, April 28, 2021 at 9:00 AM ET.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ™ (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
UKONIQ™ is a trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is the TG Therapeutics fireside chat scheduled?
Who will participate in the fireside chat at the Neuroscience Conference?
Where can I watch the TG Therapeutics fireside chat?
What is UKONIQ™ and its relevance to TG Therapeutics?
What is the focus of TG Therapeutics' research pipeline?
